Edition:
United Kingdom

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

26.68USD
12 Dec 2017
Change (% chg)

$-0.27 (-1.00%)
Prev Close
$26.95
Open
$27.05
Day's High
$27.25
Day's Low
$26.51
Volume
46,707
Avg. Vol
83,593
52-wk High
$43.30
52-wk Low
$23.18

Chart for

About

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product... (more)

Overall

Beta: 2.40
Market Cap(Mil.): $1,919.56
Shares Outstanding(Mil.): 53.83
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Theravance Biopharma ‍Files Supplemental NDA With U.S. FDA For Use Of Trelegy Ellipta​

* THERAVANCE BIOPHARMA HIGHLIGHTS SUBMISSION OF LANDMARK IMPACT DATA TO FDA TO SUPPORT EXPANDED LABEL FOR TRELEGY ELLIPTA

28 Nov 2017

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

16 Nov 2017

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

13 Nov 2017

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

07 Nov 2017

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

01 Nov 2017

BRIEF-Theravance Biopharma reports positive new data from multiple studies of VIBATIV at IDWeek 2017

* Theravance Biopharma reports positive new data from multiple studies of VIBATIV (telavancin) at IDWeek 2017

09 Oct 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

20 Sep 2017

BRIEF-Theravance Biopharma highlights approval of trelegy ellipta for treatment of appropriate patients with COPD in the U.S.

* Theravance Biopharma highlights approval of trelegy ellipta (closed triple) as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

19 Sep 2017

BRIEF-Theravance Biopharma reports Q2 revenue of $3.5 mln

* Reports second quarter 2017 financial results and provides business update

08 Aug 2017

BRIEF-Theravance Biopharma announces positive top-line results from phase 2B study of velusetrag

* Theravance Biopharma announces positive top-line results from phase 2B study of Velusetrag (TD-5108) in patients with gastroparesis

02 Aug 2017

Earnings vs. Estimates